PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9351533

Who should receive recombinant factor VIII?

P L Giangrande
View original source ↗Export metadata ↓

Abstract

Recent guidelines published by the United Kingdom Haemophilia Centre Directors' Organisation state that recombinant factor VIII constitutes the treatment of choice for all patients with haemophilia A. However, certain categories may have to be accorded priority as financial resources are limited. The general order of priority for the introduction of recombinant factor VIII is (1) previously untreated patients, (2) human immunodeficiency virus (HIV)- and hepatitis C-negative patients, (3) HIV-negative, hepatitis C-positive patients and (4) patients seropositive for anti-HIV.

Explore related subjects

Drug CostsFactor VIIIHemophilia AHumansPractice Guidelines as TopicRecombinant ProteinsUnited KingdomJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P L Giangrande. 1997. Who should receive recombinant factor VIII?. https://pubmed.ncbi.nlm.nih.gov/9351533/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Re-examining 'professionalism' in pharmacy: a South African perspective.

Although defining itself as a patient-centred profession, private sector (community and private hospital) pharmacy often appears to be that of a product-for-profit centred occupation. This perception has been at the core of the medical profession's attempts to reduce the professional autonomy of pharmacy, and has appeared at the forefront of the South African Department of Health's positioning of private sector pharmacy. Using as a starting point the debate surrounding attempts by the South African Minister of Health to regulate the price of medicines, I propose that the present negative positioning of private sector pharmacy in South Africa could be ameliorated by pharmacy practice that evidences a redefined understanding of professionalism.

Drug Costs↗